Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
|Articles|January 29, 2014
Caron Introduces New Environmental Test Chambers and Refrigerated Incubators
Author(s)Melanie Sena
Caron's New Environmental Test Chambers and Refrigerated Incubators
The new stability chambers are designed in accordance with FDA ICH Q1A Guidelines and can be used for numerous customer applications, including shelf-life studies, stability and package testing, and temperature-elevation studies. The stability chambers have several new features, including humidity control, self-closing doors with locks, CFC-free foam insulation, and a full-color user interface. These new design features help yield up to 71% in energy savings. The environmental chambers and refrigerated incubators also have a 7” color touchscreen that has easy-to-read icons and a display that can be operated with gloves on. Both products are constructed of stainless steel, making them easy to clean and highly resistant to corrosion.
Source:
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.